{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:25:15Z","timestamp":1784733915090,"version":"3.55.0"},"reference-count":165,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1124\/dmd.122.000854","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T21:10:21Z","timestamp":1679692221000},"page":"718-732","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Combined Oral Contraceptives As Victims of Drug Interactions"],"prefix":"10.1016","volume":"51","author":[{"given":"Li","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinning","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doanh","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley K.","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.122.000854_bib1","unstructured":"AbbVie (2021) ORILISSA Prescribing Information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/210450s004s005s006lbl.pdf."},{"key":"10.1124\/dmd.122.000854_bib2","doi-asserted-by":"crossref","first-page":"450","DOI":"10.5414\/CP203483","article-title":"Effect of letermovir on levonorgestrel and ethinyl estradiol pharmacokinetics","volume":"57","author":"Adedoyin","year":"2019","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.000854_bib3","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1177\/0091270004268129","article-title":"The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity","volume":"44","author":"Agrawal","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib4","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1124\/dmd.116.073940","article-title":"Metabolite identification, reaction phenotyping, and retrospective drug-drug interaction predictions of 17-deacetylnorgestimate, the active component of the oral contraceptive norgestimate","volume":"45","author":"Ahire","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000854_bib5","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1002\/jcph.1285","article-title":"FDA public meeting report on \u201cDrug interactions with hormonal contraceptives: public health and drug development implications\u201d","volume":"58","author":"Akbar","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib6","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2125.2007.03084.x","article-title":"Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects","volume":"65","author":"Andrews","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib7","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1067\/mjd.2002.120448","article-title":"Oral contraceptive efficacy and antibiotic interaction: a myth debunked","volume":"46","author":"Archer","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1124\/dmd.122.000854_bib8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/bmjebm-2020-111363","article-title":"Analysis of reports of unintended pregnancies associated with the combined use of non-enzyme-inducing antibiotics and hormonal contraceptives","volume":"26","author":"Aronson","year":"2021","journal-title":"BMJ Evid Based Med"},{"key":"10.1124\/dmd.122.000854_bib9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF00563105","article-title":"The effect of rifampicin on norethisterone pharmacokinetics","volume":"15","author":"Back","year":"1979","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib10","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/bmj.282.6275.1516","article-title":"Interaction of ethinyloestradiol with ascorbic acid in man","volume":"282","author":"Back","year":"1981","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1124\/dmd.122.000854_bib11","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2125.1988.tb03341.x","article-title":"Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics","volume":"25","author":"Back","year":"1988","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0009-9236(99)70138-4","article-title":"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive","volume":"65","author":"Barditch-Crovo","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.000854_bib13","unstructured":"Barr Laboratories (2007) AYGESTIN FDA Label https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/018405s023lbl.pdf"},{"key":"10.1124\/dmd.122.000854_bib14","unstructured":"Bayer (2022) YASMIN Prescribing Information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/021098s030lbl.pdf."},{"key":"10.1124\/dmd.122.000854_bib15","unstructured":"Boehringer Ingelheim (2022) VIRAMUNE Prescribing Information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/020636s052,020933s043lbl.pdf."},{"key":"10.1124\/dmd.122.000854_bib16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/01.fpc.0000197465.14340.d4","article-title":"Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir","volume":"16","author":"Boyd","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.122.000854_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0022-4731(77)90210-2","article-title":"Identification and measurement by gas chromatography-mass spectrometry of norethindrone and metabolites in human urine and blood","volume":"8","author":"Braselton","year":"1977","journal-title":"J Steroid Biochem"},{"key":"10.1124\/dmd.122.000854_bib18","unstructured":"Bristol-Myers Squibb (2020) REYATAZ Prescribing Information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/021567s044,206352s008lbl.pdf."},{"key":"10.1124\/dmd.122.000854_bib19","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/137192","article-title":"Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and efavirenz","volume":"2012","author":"Carten","year":"2012","journal-title":"Infect Dis Obstet Gynecol"},{"key":"10.1124\/dmd.122.000854_bib21","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1124\/jpet.103.062091","article-title":"Transport of ethinylestradiol glucuronide and ethinylestradiol sulfate by the multidrug resistance proteins MRP1, MRP2, and MRP3","volume":"309","author":"Chu","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.122.000854_bib22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/psp4.12572","article-title":"Quantitative assessment of levonorgestrel binding partner interplay and drug-drug interactions using physiologically based pharmacokinetic modeling","volume":"10","author":"Cicali","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib23","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/j.1365-2125.1990.tb05457.x","article-title":"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids","volume":"30","author":"Crawford","year":"1990","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib24","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1528-1167.2010.02917.x","article-title":"Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding","volume":"52","author":"Davis","year":"2011","journal-title":"Epilepsia"},{"key":"10.1124\/dmd.122.000854_bib25","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00228-012-1287-5","article-title":"The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects","volume":"68","author":"Davis","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib26","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/cid\/cis824","article-title":"Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir","volume":"56","author":"de Kanter","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1124\/dmd.122.000854_bib27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cpdd.283","article-title":"Pharmacokinetic and pharmacodynamic evaluation of the drug-drug interaction between isavuconazole and warfarin in healthy subjects","volume":"6","author":"Desai","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1124\/dmd.122.000854_bib28","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1046\/j.1528-1157.2003.55602.x","article-title":"Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects","volume":"44","author":"Doose","year":"2003","journal-title":"Epilepsia"},{"key":"10.1124\/dmd.122.000854_bib29","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0026-895X(25)13456-1","article-title":"Human bilirubin UDP-glucuronosyltransferase catalyzes the glucuronidation of ethinylestradiol","volume":"43","author":"Ebner","year":"1993","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib30","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.contraception.2010.04.016","article-title":"Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review","volume":"82","author":"Edelman","year":"2010","journal-title":"Contraception"},{"key":"10.1124\/dmd.122.000854_bib31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0010-7824(00)00195-5","article-title":"The possible role of enterohepatic cycling on bioavailability of norethisterone and gestodene in women using combined oral contraceptives","volume":"63","author":"Elomaa","year":"2001","journal-title":"Contraception"},{"key":"10.1124\/dmd.122.000854_bib32","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/cpt.1085","article-title":"Risk-benefit assessment of ethinylestradiol using a physiologically based pharmacokinetic modeling approach","volume":"104","author":"Ezuruike","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.000854_bib33","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.eplepsyres.2013.04.009","article-title":"Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects","volume":"106","author":"Falc\u00e3o","year":"2013","journal-title":"Epilepsy Res"},{"key":"10.1124\/dmd.122.000854_bib34","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.eplepsyres.2013.02.020","article-title":"Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol\/levonorgestrel oral contraceptive in healthy women","volume":"105","author":"Falc\u00e3o","year":"2013","journal-title":"Epilepsy Res"},{"key":"10.1124\/dmd.122.000854_bib35","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1528-1157.1999.tb00779.x","article-title":"Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women","volume":"40","author":"Fattore","year":"1999","journal-title":"Epilepsia"},{"key":"10.1124\/dmd.122.000854_bib36","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s40262-021-00989-0","article-title":"Pharmacokinetic and pharmacodynamic profiles of ethinylestradiol\/norgestimate combination or norethindrone upon coadministration with elagolix 150 mg once daily in healthy premenopausal women","volume":"60","author":"Feldman","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.122.000854_bib37","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1363\/3809006","article-title":"Disparities in rates of unintended pregnancy in the United States, 1994 and 2001","volume":"38","author":"Finer","year":"2006","journal-title":"Perspect Sex Reprod Health"},{"key":"10.1124\/dmd.122.000854_bib38","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1056\/NEJMsa1506575","article-title":"Declines in unintended pregnancy in the United States, 2008-2011","volume":"374","author":"Finer","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.122.000854_bib39","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1177\/0091270011419855","article-title":"The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevir","volume":"52","author":"Garg","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib40","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/oxfordjournals.aje.a115799","article-title":"Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease","volume":"133","author":"Gerstman","year":"1991","journal-title":"Am J Epidemiol"},{"key":"10.1124\/dmd.122.000854_bib41","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S0002-9378(89)80010-9","article-title":"Pharmacology of contraceptive steroids: a brief review","volume":"160","author":"Goldzieher","year":"1989","journal-title":"Am J Obstet Gynecol"},{"key":"10.1124\/dmd.122.000854_bib42","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/0002-9378(90)90550-Q","article-title":"Pharmacokinetics of ethinyl estradiol and mestranol","volume":"163","author":"Goldzieher","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"10.1124\/dmd.122.000854_bib43","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/0024-3205(90)90431-P","article-title":"Metabolism of 17 alpha-ethynylestradiol in humans","volume":"47","author":"Guengerich","year":"1990","journal-title":"Life Sci"},{"key":"10.1124\/dmd.122.000854_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.386","article-title":"Rifampin modulation of xeno- and endobiotic conjugating enzyme mRNA expression and associated microRNAs in human hepatocytes","volume":"6","author":"Gufford","year":"2018","journal-title":"Pharmacol Res Perspect"},{"key":"10.1124\/dmd.122.000854_bib45","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.clpt.2003.08.009","article-title":"The interaction between St John\u2019s wort and an oral contraceptive","volume":"74","author":"Hall","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.000854_bib46","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0010-7824(02)00473-0","article-title":"Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties","volume":"67","author":"Hammond","year":"2003","journal-title":"Contraception"},{"key":"10.1124\/dmd.122.000854_bib47","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1124\/dmd.109.031526","article-title":"Transporter studies with the 3-O-sulfate conjugate of 17alpha-ethinylestradiol: assessment of human kidney drug transporters","volume":"38","author":"Han","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000854_bib48","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1124\/dmd.109.031518","article-title":"Transporter studies with the 3-O-sulfate conjugate of 17alpha-ethinylestradiol: assessment of human liver drug transporters","volume":"38","author":"Han","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000854_bib49","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1124\/dmd.116.074567","article-title":"Considerations from the IQ Induction Working Group in response to drug-drug interaction guidance from regulatory agencies: focus on downregulation, CYP2C induction, and CYP2B6 positive control","volume":"45","author":"Hariparsad","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000854_bib50","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/cpt.2689","article-title":"Ziritaxestat drug-drug interaction with oral contraceptives: role of SULT1E1 inhibition","volume":"112","author":"Helmer","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.000854_bib51","first-page":"218","article-title":"Evaluation of interaction between fluconazole and an oral contraceptive in healthy women","volume":"98","author":"Hilbert","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1124\/dmd.122.000854_bib52","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1086\/588794","article-title":"Atazanavir modestly increases plasma levels of raltegravir in healthy subjects","volume":"47","author":"Iwamoto","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1124\/dmd.122.000854_bib53","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1128\/AAC.01543-07","article-title":"Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir","volume":"52","author":"Iwamoto","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.122.000854_bib54","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/bcp.12428","article-title":"Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir","volume":"78","author":"Johnson","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib55","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/jcph.418","article-title":"Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers","volume":"55","author":"Joseph","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib56","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/jcph.214","article-title":"The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects","volume":"54","author":"Kakuda","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib57","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.clinthera.2011.08.012","article-title":"Effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy women","volume":"33","author":"Kasserra","year":"2011","journal-title":"Clin Ther"},{"key":"10.1124\/dmd.122.000854_bib58","first-page":"83","article-title":"Use of contraception among reproductive-aged women in the United States, 2014 and 2016","volume":"1","author":"Kavanaugh","year":"2020","journal-title":"F S Rep"},{"key":"10.1124\/dmd.122.000854_bib59","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1200\/JCO.2002.08.177","article-title":"Modulation of irinotecan metabolism by ketoconazole","volume":"20","author":"Kehrer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.122.000854_bib60","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/bmj.1.5801.686-c","article-title":"Unplanned pregnancy in an epileptic","volume":"1","author":"Kenyon","year":"1972","journal-title":"BMJ"},{"key":"10.1124\/dmd.122.000854_bib61","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1128\/AAC.02605-15","article-title":"Evaluation of drug-drug interactions between direct-acting anti-hepatitis C virus combination regimens and the HIV-1 antiretroviral agents raltegravir, tenofovir, emtricitabine, efavirenz, and rilpivirine","volume":"60","author":"Khatri","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.122.000854_bib62","doi-asserted-by":"crossref","first-page":"6244","DOI":"10.1128\/AAC.00795-16","article-title":"Drug-drug interaction between the direct-acting antiviral regimen of ombitasvir-paritaprevir-ritonavir plus dasabuvir and the HIV antiretroviral agent dolutegravir or abacavir plus lamivudine","volume":"60","author":"Khatri","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.122.000854_bib63","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1023\/B:PHAM.0000033017.52484.81","article-title":"P-glycoprotein (P-gp\/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro","volume":"21","author":"Kim","year":"2004","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.122.000854_bib64","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1124\/dmd.111.038646","article-title":"Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir","volume":"39","author":"Kirby","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000854_bib65","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s40268-017-0205-9","article-title":"Boceprevir and antiretroviral pharmacokinetic interactions in HIV\/HCV co-infected persons: AIDS Clinical Trials Group study A5309s","volume":"17","author":"Kiser","year":"2017","journal-title":"Drugs R D"},{"key":"10.1124\/dmd.122.000854_bib66","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/j.1528-1157.1992.tb01773.x","article-title":"Possible interaction between oxcarbazepine and an oral contraceptive","volume":"33","author":"Klosterskov Jensen","year":"1992","journal-title":"Epilepsia"},{"key":"10.1124\/dmd.122.000854_bib67","doi-asserted-by":"crossref","first-page":"8392","DOI":"10.1093\/nar\/gkr458","article-title":"Liganded pregnane X receptor represses the human sulfotransferase SULT1E1 promoter through disrupting its chromatin structure","volume":"39","author":"Kodama","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/dmd.122.000854_bib68","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jsbmb.2007.09.025","article-title":"Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone","volume":"110","author":"Korhonen","year":"2008","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1124\/dmd.122.000854_bib69","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0010-7824(00)00133-5","article-title":"Drospirenone: pharmacology and pharmacokinetics of a unique progestogen","volume":"62","author":"Krattenmacher","year":"2000","journal-title":"Contraception"},{"key":"10.1124\/dmd.122.000854_bib70","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2125.1994.tb04262.x","article-title":"Interaction between tolbutamide and ketoconazole in healthy subjects","volume":"37","author":"Krishnaiah","year":"1994","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 3","key":"10.1124\/dmd.122.000854_bib71","doi-asserted-by":"crossref","first-page":"S327","DOI":"10.1093\/clinids\/12.Supplement_3.S327","article-title":"Drug interactions with fluconazole","volume":"12","author":"Lazar","year":"1990","journal-title":"Rev Infect Dis"},{"key":"10.1124\/dmd.122.000854_bib72","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1177\/009127009803801109","article-title":"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone","volume":"38","author":"LeBel","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib73","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/psp4.12357","article-title":"Establishing a multidisciplinary framework to study drug-drug interactions of hormonal contraceptives: an invitation to collaborate","volume":"7","author":"Lesko","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib74","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1046\/j.1365-2125.1999.00081.x","article-title":"Effects of cytochrome P450 inducers on 17alpha-ethinyloestradiol (EE2) conjugation by primary human hepatocytes","volume":"48","author":"Li","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib75","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1080\/00498254.2020.1737759","article-title":"Evaluation of in vitro absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor","volume":"50","author":"Liao","year":"2020","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.122.000854_bib76","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00280-021-04338-7","article-title":"A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors","volume":"88","author":"Liao","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib77","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/00126334-200408150-00006","article-title":"Coadministration of lopinavir\/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction","volume":"36","author":"Lim","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1124\/dmd.122.000854_bib78","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s00228-014-1711-0","article-title":"Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol\/norethindrone","volume":"70","author":"Lin","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib79","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/00912709922007985","article-title":"Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent","volume":"39","author":"Loi","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib80","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.bios.2015.05.003","article-title":"An optimized ratiometric fluorescent probe for sensing human UDP-glucuronosyltransferase 1A1 and its biological applications","volume":"72","author":"Lv","year":"2015","journal-title":"Biosens Bioelectron"},{"key":"10.1124\/dmd.122.000854_bib81","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/1872312808666140606101422","article-title":"Direct and rapid transcript analysis assay for CYP mRNA expression and inducibility in human primary hepatocytes","volume":"8","author":"Mattinen","year":"2014","journal-title":"Drug Metab Lett"},{"key":"10.1124\/dmd.122.000854_bib82","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1089\/cap.2015.0117","article-title":"Serum quetiapine concentration changes with concomitant oxcarbazepine therapy in a boy with autism spectrum disorder","volume":"25","author":"McGrane","year":"2015","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1124\/dmd.122.000854_bib83","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhep.2015.01.026","article-title":"Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir\/ritonavir, ombitasvir, and dasabuvir","volume":"63","author":"Menon","year":"2015","journal-title":"J Hepatol"},{"key":"10.1124\/dmd.122.000854_bib84","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2174\/18755453MTE05NDYa1","article-title":"Absorption, metabolism, distribution, and excretion of letermovir","volume":"22","author":"Menzel","year":"2021","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.122.000854_bib85","unstructured":"Merck & Co. (2021) ISENTRESS Prescribing Information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/022145s044,203045s017,205786s009lbl.pdf."},{"key":"10.1124\/dmd.122.000854_bib86","unstructured":"Merck & Co. (2017) VICTRELIS Prescribing Information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/202258s016lbl.pdf."},{"key":"10.1124\/dmd.122.000854_bib87","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ijantimicag.2014.12.035","article-title":"Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV\/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders","volume":"45","author":"Milazzo","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1124\/dmd.122.000854_bib88","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s00228-013-1556-y","article-title":"A randomised study of the effect of danoprevir\/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail","volume":"69","author":"Morcos","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib89","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1124\/jpet.117.247296","article-title":"Establishing transcriptional signatures to differentiate PXR-, CAR-, and AhR-mediated regulation of drug metabolism and transport genes in cryopreserved human hepatocytes","volume":"365","author":"Moscovitz","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.122.000854_bib90","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.contraception.2004.11.004","article-title":"Interaction of St. John\u2019s wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding","volume":"71","author":"Murphy","year":"2005","journal-title":"Contraception"},{"key":"10.1124\/dmd.122.000854_bib91","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40262-020-00921-y","article-title":"Drug-drug interaction studies of elagolix with oral and transdermal low-dose hormonal add-back therapy","volume":"60","author":"Nader","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.122.000854_bib92","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/j.xphs.2018.05.008","article-title":"Characterization of CYP2C induction in cryopreserved human hepatocytes and its application in the prediction of the clinical consequences of the induction","volume":"107","author":"Nagai","year":"2018","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.122.000854_bib93","series-title":"CRIXIVAN: Clinical Pharmacology and Biopharmaceutics Review.","year":"1996"},{"key":"10.1124\/dmd.122.000854_bib94","series-title":"KETEK: Clinical Pharmacology and Biopharmaceutics Review.","year":"2004"},{"key":"10.1124\/dmd.122.000854_bib95","series-title":"KALETRA: Clinical Pharmacology and Biopharmaceutics Review.","year":"2000"},{"key":"10.1124\/dmd.122.000854_bib96","series-title":"REYATAZ: Clinical Pharmacology and Biopharmaceutics Review.","year":"2003"},{"key":"10.1124\/dmd.122.000854_bib97","series-title":"BANZEL: Clinical Pharmacology and Biopharmaceutics Review.","year":"2008"},{"key":"10.1124\/dmd.122.000854_bib98","series-title":"INTELENCE: Clinical Pharmacology and Biopharmaceutics Review.","year":"2008"},{"key":"10.1124\/dmd.122.000854_bib99","series-title":"MULTAQ: Clinical Pharmacology and Biopharmaceutics Review.","year":"2009"},{"key":"10.1124\/dmd.122.000854_bib100","series-title":"INCIVEK: Clinical Pharmacology and Biopharmaceutics Review.","year":"2011"},{"key":"10.1124\/dmd.122.000854_bib101","series-title":"VICTRELIS: Clinical Pharmacology and Biopharmaceutics Review.","year":"2011"},{"key":"10.1124\/dmd.122.000854_bib102","series-title":"FYCOMPA: Clinical Pharmacology and Biopharmaceutics Review.","year":"2012"},{"key":"10.1124\/dmd.122.000854_bib103","series-title":"AUBAGIO: Clinical Pharmacology and Biopharmaceutics Review.","year":"2012"},{"key":"10.1124\/dmd.122.000854_bib104","series-title":"BRIVIACT: Clinical Pharmacology and Biopharmaceutics Review.","year":"2016"},{"key":"10.1124\/dmd.122.000854_bib105","series-title":"VIEKIRA PAK: Clinical Pharmacology and Biopharmaceutics Review.","year":"2014"},{"key":"10.1124\/dmd.122.000854_bib106","series-title":"PREVYMIS: Clinical Pharmacology and Biopharmaceutics Review.","year":"2017"},{"key":"10.1124\/dmd.122.000854_bib107","series-title":"ORILISSA: Clinical Pharmacology and Biopharmaceutics Review.","year":"2018"},{"key":"10.1124\/dmd.122.000854_bib108","series-title":"RIMEGEPANT SULFATE: Clinical Pharmacology and Biopharmaceutics Review.","year":"2020"},{"key":"10.1124\/dmd.122.000854_bib109","series-title":"RUKOBIA: Clinical Pharmacology and Biopharmaceutics Review.","year":"2020"},{"key":"10.1124\/dmd.122.000854_bib110","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1124\/dmd.31.8.1043","article-title":"Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition","volume":"31","author":"Neal","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000854_bib111","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2125.1998.00749.x","article-title":"Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers","volume":"46","author":"Ouellet","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib112","unstructured":"Pfizer (2022) DIFLUCAN Prescribing Information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/019949Orig1s071,019950Orig1s070,020090Orig1s052lbl.pdf."},{"key":"10.1124\/dmd.122.000854_bib113","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/jcph.1689","article-title":"Assessment of clinical drug-drug interactions of elagolix, a gonadotropin-releasing hormone receptor antagonist","volume":"60","author":"Polepally","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib114","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1177\/00912700122010311","article-title":"Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects","volume":"41","author":"Prueksaritanont","year":"2001","journal-title":"J Clin Pharmacol"},{"issue":"Suppl 1","key":"10.1124\/dmd.122.000854_bib115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.1365-2125.2003.01997.x","article-title":"Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib116","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/hiv.13136","article-title":"In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel","volume":"22","author":"Roberts","year":"2021","journal-title":"HIV Med"},{"key":"10.1124\/dmd.122.000854_bib117","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/cpt.2383","article-title":"Drug interactions involving 17\u03b1-ethinylestradiol: considerations beyond cytochrome P450 3A induction and inhibition","volume":"111","author":"Rodrigues","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.000854_bib118","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jpba.2018.02.029","article-title":"Application of ultra high-performance liquid chromatography tandem mass spectrometry to investigate the regioselective glucuronidation of icaritin in vitro","volume":"154","author":"Rong","year":"2018","journal-title":"J Pharm Biomed Anal"},{"key":"10.1124\/dmd.122.000854_bib119","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0002-9378(98)70047-X","article-title":"Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons","volume":"179","author":"Rosenberg","year":"1998","journal-title":"Am J Obstet Gynecol"},{"key":"10.1124\/dmd.122.000854_bib120","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/jcph.436","article-title":"Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: in vitro and in vivo correlation","volume":"55","author":"Sabo","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib121","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1128\/AAC.03589-14","article-title":"Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers","volume":"59","author":"Sabo","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.122.000854_bib122","unstructured":"Sanofi-Aventis U.S. (2015) KETEK Prescribing Information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/021144s019lbl.pdf."},{"key":"10.1124\/dmd.122.000854_bib123","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/EDE.0000000000001302","article-title":"A pharmacoepidemiologic approach to evaluate real-world effectiveness of hormonal contraceptives in the presence of drug-drug interactions","volume":"32","author":"Sarayani","year":"2021","journal-title":"Epidemiology"},{"key":"10.1124\/dmd.122.000854_bib124","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.contraception.2009.01.009","article-title":"Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone","volume":"80","author":"Sch\u00f6ller-Gy\u00fcre","year":"2009","journal-title":"Contraception"},{"key":"10.1124\/dmd.122.000854_bib125","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1124\/dmd.32.11.1299","article-title":"Sulfotransferase 1E1 is a low km isoform mediating the 3-O-sulfation of ethinyl estradiol","volume":"32","author":"Schrag","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000854_bib126","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1177\/0091270009337131","article-title":"The effect of etoricoxib on the pharmacokinetics of oral contraceptives in healthy participants","volume":"49","author":"Schwartz","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib127","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1177\/0091270007299758","article-title":"The effect of etoricoxib on the pharmacodynamics and pharmacokinetics of warfarin","volume":"47","author":"Schwartz","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib128","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3851\/IMP1725","article-title":"The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women","volume":"16","author":"Sevinsky","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1124\/dmd.122.000854_bib129","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/j.1875-9114.1998.tb03161.x","article-title":"Enhanced metabolism of levonorgestrel during phenobarbital treatment and resultant pregnancy","volume":"18","author":"Shane-McWhorter","year":"1998","journal-title":"Pharmacotherapy"},{"key":"10.1124\/dmd.122.000854_bib130","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S0002-9378(98)80016-1","article-title":"The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives","volume":"178","author":"Sinofsky","year":"1998","journal-title":"Am J Obstet Gynecol"},{"key":"10.1124\/dmd.122.000854_bib131","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0010-7824(75)90094-3","article-title":"The presence of dl-, d- and l-norgestrel and their metabolites in the plasma of women","volume":"12","author":"Sisenwine","year":"1975","journal-title":"Contraception"},{"key":"10.1124\/dmd.122.000854_bib132","doi-asserted-by":"crossref","first-page":"550","DOI":"10.5414\/CP202321","article-title":"Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women","volume":"53","author":"Sivasubramanian","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.000854_bib133","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/jbt.20058","article-title":"Modulation of UDP-glucuronosyltransferase 1A1 in primary human hepatocytes by prototypical inducers","volume":"19","author":"Smith","year":"2005","journal-title":"J Biochem Mol Toxicol"},{"key":"10.1124\/dmd.122.000854_bib134","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2125.2011.03947.x","article-title":"Effect of atazanavir and atazanavir\/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S\/GSK1349572","volume":"72","author":"Song","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib135","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1128\/AAC.00073-11","article-title":"Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir","volume":"55","author":"Song","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.122.000854_bib136","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/0091270010371113","article-title":"The effect of lopinavir\/ritonavir and darunavir\/ritonavir on the HIV integrase inhibitor S\/GSK1349572 in healthy participants","volume":"51","author":"Song","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib137","doi-asserted-by":"crossref","first-page":"13801","DOI":"10.1073\/pnas.212494599","article-title":"Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR)","volume":"99","author":"Sonoda","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.122.000854_bib138","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.contraception.2012.12.011","article-title":"Ethinyl estradiol and 17\u03b2-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment","volume":"87","author":"Stanczyk","year":"2013","journal-title":"Contraception"},{"key":"10.1124\/dmd.122.000854_bib139","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0010-7824(90)90093-B","article-title":"Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids","volume":"42","author":"Stanczyk","year":"1990","journal-title":"Contraception"},{"key":"10.1124\/dmd.122.000854_bib140","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/jcph.187","article-title":"Effect of brivaracetam (400 mg\/day) on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women","volume":"53","author":"Stockis","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib141","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/jcph.446","article-title":"Effect of brivaracetam on CYP3A activity, measured by oral midazolam","volume":"55","author":"Stockis","year":"2015","journal-title":"J Clin Pharmacol"},{"issue":"Suppl 2","key":"10.1124\/dmd.122.000854_bib142","first-page":"S49","article-title":"Drug-drug interaction studies with oral contraceptives: pharmacokinetic\/pharmacodynamic and study design considerations","volume":"60","author":"Sun","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib143","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1363\/psrh.12017","article-title":"Contraceptive failure in the United States: estimates from the 2006-2010 National Survey of Family Growth","volume":"49","author":"Sundaram","year":"2017","journal-title":"Perspect Sex Reprod Health"},{"key":"10.1124\/dmd.122.000854_bib144","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1089\/omi.2019.0122","article-title":"MicroRNA mediated changes in drug metabolism and target gene expression by efavirenz and rifampicin in vitro: clinical implications","volume":"23","author":"Swart","year":"2019","journal-title":"OMICS"},{"key":"10.1124\/dmd.122.000854_bib145","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2165\/00003088-200847110-00002","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib","volume":"47","author":"Takemoto","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.122.000854_bib146","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2125.1992.tb04111.x","article-title":"Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man","volume":"34","author":"Touchette","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib147","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cpdd.285","article-title":"Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol\/norethindrone in healthy adults","volume":"6","author":"Townsend","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1124\/dmd.122.000854_bib148","doi-asserted-by":"crossref","first-page":"113","DOI":"10.5414\/CPP44113","article-title":"Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol","volume":"44","author":"van Giersbergen","year":"2006","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.000854_bib149","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2921","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study","volume":"339","author":"van Hylckama Vlieg","year":"2009","journal-title":"BMJ"},{"key":"10.1124\/dmd.122.000854_bib150","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/bcp.14148","article-title":"Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir\/ritonavir plus dasabuvir in adults with human immunodeficiency virus-1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub-study A5334s","volume":"86","author":"Venuto","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib151","unstructured":"ViiV Healthcare (2020) RUKOBIA Prescribing Information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212950s000lbl.pdf."},{"key":"10.1124\/dmd.122.000854_bib152","unstructured":"ViiV Healthcare (2019) TIVICAY Prescribing Information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/204790s028,213983s002lbl.pdf."},{"key":"10.1124\/dmd.122.000854_bib153","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/00912700122009728","article-title":"Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors","volume":"41","author":"von Moltke","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib154","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/j.2042-7158.1998.tb04000.x","article-title":"Enterohepatic cycling and pharmacokinetics of oestradiol in postmenopausal women","volume":"50","author":"Vree","year":"1998","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib155","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1124\/dmd.104.000182","article-title":"The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol","volume":"32","author":"Wang","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000854_bib156","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1111\/bcp.12745","article-title":"Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol","volume":"80","author":"Wiesinger","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000854_bib157","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/cpt.1848","article-title":"The effects of weak and strong CYP3A induction by rifampicin on the pharmacokinetics of five progestins and ethinylestradiol compared to midazolam","volume":"108","author":"Wiesinger","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.000854_bib158","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/cts.12600","article-title":"Evaluation of drug-drug interactions of rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp substrates in patients with an advanced solid tumor","volume":"12","author":"Xiao","year":"2019","journal-title":"Clin Transl Sci"},{"key":"10.1124\/dmd.122.000854_bib159","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2133\/dmpk.DMPK-12-RG-124","article-title":"In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19","volume":"28","author":"Xu","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.122.000854_bib160","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/cpdd.282","article-title":"Pharmacokinetic interaction between isavuconazole and a fixed-dose combination of lopinavir 400 mg\/ritonavir 100 mg in healthy subjects","volume":"6","author":"Yamazaki","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1124\/dmd.122.000854_bib161","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/01.qai.0000219774.20174.64","article-title":"Lopinavir\/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers","volume":"42","author":"Yeh","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1124\/dmd.122.000854_bib162","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00007691-199302000-00007","article-title":"Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine","volume":"15","author":"Zaccara","year":"1993","journal-title":"Ther Drug Monit"},{"key":"10.1124\/dmd.122.000854_bib163","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1124\/dmd.105.005447","article-title":"In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation","volume":"33","author":"Zhang","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000854_bib164","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/00003088-200746020-00003","article-title":"Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug","volume":"46","author":"Zhang","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.122.000854_bib165","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3851\/IMP1724","article-title":"The effect of atazanavir\/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women","volume":"16","author":"Zhang","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1124\/dmd.122.000854_bib166","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/cts.12499","article-title":"Role of CYP3A in oral contraceptives clearance","volume":"11","author":"Zhang","year":"2018","journal-title":"Clin Transl Sci"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624009875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624009875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.122.000854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:02:45Z","timestamp":1739955765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624009875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":165,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0090955624009875"],"URL":"https:\/\/doi.org\/10.1124\/dmd.122.000854","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined Oral Contraceptives As Victims of Drug Interactions","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.122.000854","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"U.S. Government work not protected by U.S. copyright","name":"copyright","label":"Copyright"}]}}